Single-dose administration of Factor VIIa
The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
1. A method for treating a bleeding episode in a subject in need of such treatment, said method comprising administering intravenously to said subject a purified Factor VIIa equivalent, wherein said administering is in a single dose and said dose comprises a single-dose-effective amount of said Factor VIIa equivalent wherein said single-dose-effective amount comprises between 250 and 500 μg/kg Factor VIIa equivalent, and wherein, subsequent to said administration, no further Factor VIIa equivalent is administered to said subject for a period of at least 4 hours, wherein said Factor VIIa equivalent exhibits at least about 30% of the coagulant activity of Factor VIIa on a molar basis, and wherein said Factor VIIa equivalent is a Factor VII polypeptide that has been chemically modified relative to human Factor VIIa and/or contains one or more amino acid sequence alterations relative to human Factor VIIa.
2. A method as defined in claim 1 , wherein said period is at least about 24 hours.
3. A method as defined in claim 1 , wherein said single dose is administered over a period of less than about 5 minutes.
4. A method as defined in claim 1 , wherein said single-dose-effective amount comprises between about 300 and about 500 μg/kg Factor VIIa equivalent.
5. A method as defined in claim 1 , wherein said Factor VIIa equivalent is selected from the group consisting of: S52A-FV11, S60A-FV11; L305-FVII, L305V/M306D/D309S-FVII, L305I-FVII, L305T-FVII, F374P-FVII, V158T/M298Q-FVII, V158D/E296V/M298Q-FVII, K337A-FVII, M298Q-FVII, V158D/M298Q-FVII, L305V/K337A-FVII, V158D/E296V/M298Q/L305V-FVII, K157A-FVII, E296V-FVII, E296V/M298Q-FVII, V158D/E296V-FVII, V158D/M298K-FVII, and S336G-FVII; Factor VIIa that has been proteolytically cleaved between residues 290 and 291; Factor VIIa that has been proteolytically cleaved between residues 315 and 316; and oxidized forms of Factor VIIa.
6. A method as defined in claim 1 , further comprising administering, in said single dose, or substantially simultaneously with said single dose, a second coagulant agent.
7. A method as defined in claim 6 , wherein said second coagulant agent is selected from the group consisting of Factor VII, Factor VIII, Factor IX, and Factor XIII.
8. A method as defined in claim 1 , further comprising administering an anticoagulant, wherein said anticoagulant is administered in said single dose, or substantially simultaneously with said single dose.
9. A method for treating a bleeding episode, said method comprising administering to a subject in need of such treatment (i) a first amount of a Factor VIIa equivalent and (ii) a second amount of second coagulant agent, wherein said first amount comprises between 250 and 500 μg/kg Factor VIIa equivalent and wherein said first and second amounts together comprise an aggregate effective amount for treating said bleeding and said aggregate effective amount is administered in a single dose, and wherein, subsequent to said administration, no further Factor VIIa equivalent is administered to said subject for a period of at least 4 hours, wherein said Factor VIIa equivalent exhibits at least about 30% of the coagulant activity of Factor VIIa on a molar basis, and wherein said Factor VIIa equivalent is a Factor VII polypeptide that has been chemically modified relative to human Factor VIIa and/or contains one or more amino acid sequence alterations relative to human Factor VIIa.